Lupin has received approval from the US Food and Drug Administration (USFDA) to market Valbenazine Capsules in strength of 40 mg and 80 mg. This medication is equivalent to Neurocrine Biosciences, Inc's Ingrezza Capsules.
The company is one of the first abbreviated new drug application (ANDA) applicants and is eligible for 180 days of shared generic exclusivity. As per the IQVIA MAT data, Valbenazine Capsules, 40 mg and 80 mg had estimated annual sales of $1,621 million in the US.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
